DMed

About DMed

In 2016, Dr. Lingshi Tan founded dMed Biopharmaceutical Co., Ltd., a company with a vision to revolutionize clinical research. With a strategic presence in 23 countries, dMed aimed to provide broad access to diverse patient populations across the Americas, Europe, and APAC. The company quickly established itself as a leader in the healthcare industry, leveraging its therapeutic and operational expertise to conduct efficient and high-standard clinical studies.

In a significant turn of events, dMed merged with Clinipace in 2021, forming a new entity known as Caidya. This merger combined the strengths of two leading Contract Research Organizations (CROs), expanding their global footprint and enhancing their capabilities in clinical trial management. The newly formed Caidya boasted nearly 1,800 employees across more than 30 countries, marking a new era of growth and innovation.

In 2025, Caidya achieved a major milestone by securing a $165 million strategic funding round from Rubicon Founders. This infusion of capital was aimed at further expanding their global operations and enhancing their technological infrastructure to ensure transparency and data-driven decision-making in clinical trials.

Today, Caidya stands as a testament to the power of strategic mergers and visionary leadership in the biopharmaceutical industry. With a commitment to bringing life-changing therapies to patients worldwide, Caidya continues to push the boundaries of clinical research, driven by a mission to improve patient outcomes through innovative and patient-focused solutions.